GENOR BIOPHARMA DL-00002 (67N0) — Tangible Net Worth Ratio
GENOR BIOPHARMA DL-00002 (67N0) has a Tangible Net Worth Ratio of 100.0% as of June 2025. This metric is calculated by deducting intangible assets (€0.00) from net assets (€1.10 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See net assets of GENOR BIOPHARMA DL-00002 for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
GENOR BIOPHARMA DL-00002 Tangible Net Worth Ratio (2021–2024)
This chart shows how GENOR BIOPHARMA DL-00002's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 100.0%, reflecting net assets of €1.10 Billion with intangible assets of €0.00 EUR. Also explore how fast is GENOR BIOPHARMA DL-00002 growing its equity to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for GENOR BIOPHARMA DL-00002 (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for GENOR BIOPHARMA DL-00002 from 2021 to 2024, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see GENOR BIOPHARMA DL-00002 stock valuation.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 92.8% | €1.15 Billion | €82.65 Million | €1.29 Billion | ▲ +0.6 pp |
| 2023 | 92.2% | €1.19 Billion | €92.28 Million | €1.45 Billion | ▲ +0.1 pp |
| 2022 | 92.2% | €1.81 Billion | €141.46 Million | €2.12 Billion | ▼ -1.8 pp |
| 2021 | 94.0% | €2.49 Billion | €149.29 Million | €2.86 Billion | — |